title: Reply to S.E. Krown et al.
authors.affiliation: National Centre for HIV Malignancy, Chelsea and Westminster Hospital, London, United Kingdom.
authors.forename: Lami
authors.initials: L
authors.lastname: Akindele
authors.affiliation: National Centre for HIV Malignancy, Chelsea and Westminster Hospital, London, United Kingdom M.Bower@imperial.ac.uk.
authors.forename: Mark
authors.initials: M
authors.lastname: Bower
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy*; D018943:Anthracyclines / Q000627:therapeutic use*; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D012514:Sarcoma, Kaposi / Q000188:drug therapy*
chemical_list: D018943:Anthracyclines; D019380:Anti-HIV Agents; D000903:Antibiotics, Antineoplastic